Drug Profile
Cancer vaccine - AGC Biologics/San Raffaele Scientific Institute
Alternative Names: M3TKLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator MolMed
- Developer MolMed; Scientific Institute San Raffaele
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 17 Sep 2015 No recent reports of development identified - Phase-I/II for Malignant melanoma in Italy (IV)
- 29 Jun 2009 Phase-I/II development is ongoing in Italy
- 30 Nov 2007 This vaccine is available for licensing in all territories except Asia (http://www.molmed.com)